Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine

被引:3
|
作者
Theodorakis, Nikolaos [1 ,2 ,3 ]
Kreouzi, Magdalini [4 ]
Hitas, Christos [3 ]
Anagnostou, Dimitrios [3 ]
Nikolaou, Maria [3 ]
机构
[1] Clin Metab & Athlet Performance, NT Cardiometab, Palaio Faliro 17564, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens 11527, Greece
[3] Sismanogleio Amalia Fleming Gen Hosp, Dept Cardiol, Melissia 15127, Greece
[4] Sismanogleio Amalia Fleming Gen Hosp, Dept Internal Med, Melissia 15127, Greece
关键词
growth hormone; insulin-like growth factor-I; heart failure; anabolic hormones; multiple hormonal deficiency syndrome; randomized controlled trials; precision medicine; LEFT-VENTRICULAR FUNCTION; HUMAN GH THERAPY; EXERCISE CAPACITY; PERFORMANCE; DEFICIENCY;
D O I
10.3390/diagnostics14242831
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) remains a major cause of morbidity and mortality worldwide. While standard treatments primarily target neurohormonal pathways, emerging evidence highlights the significant role of hormonal deficiencies, such as impaired growth hormone (GH) signaling, in HF progression and outcomes. GH is crucial for cardiovascular and skeletal muscle function, and its deficiency has been associated with worse prognosis. This review synthesizes recent findings from randomized controlled trials (RCTs) to explore how GH can contribute to personalized care and improve patient stratification in HF. A comprehensive literature review was conducted using PubMed up to 10 October 2024. Search terms included "growth hormone" combined with "heart failure", "HFrEF", "HFpEF", and "HFmrEF." Only placebo-controlled RCTs published in English and involving human subjects were considered. Data on study design, participant characteristics, GH dosing, and key clinical outcomes were systematically extracted and analyzed. Several trials demonstrated that GH therapy can transiently improve left ventricular ejection fraction (LVEF), exercise capacity, and reduce inflammatory markers. For example, one study has reported an increase in LVEF from 32 +/- 3.8% to 43.8 +/- 4.6% (p = 0.002), following three months of GH therapy in post-MI HF patients. However, benefits diminished after discontinuation. Additional studies have observed sustained improvements in peak oxygen consumption and LVEF over four years, with an additional trend towards hard endpoint improvement. Conversely, some studies showed no significant impact on cardiac function, highlighting heterogeneity in outcomes. As a result, GH therapy holds promise for improving cardiac and functional parameters in HF patients, but evidence remains mixed. Larger, long-term RCTs are needed to confirm its efficacy and safety. Precision medicine approaches and biomarker-driven strategies may optimize patient outcomes and guide clinical practice.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Dying with a Broken Heart: Palliative Medicine for the Heart Failure Patient
    Puri, Sunita
    JOURNAL OF CARDIAC FAILURE, 2022, 28 : 14 - 14
  • [32] Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview
    Shah, Sanjiv J.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2017, 10 (03) : 233 - 244
  • [33] Growth hormone, vascular reactivity, and heart failure
    Raffaele Napoli
    European Journal of Clinical Pharmacology, 2006, 62 : 141 - 144
  • [34] Narrative review of pediatric heart failure in the age of precision medicine
    Valikodath, Nishma
    Godown, Justin
    Sheybani, Aryaz
    TRANSLATIONAL PEDIATRICS, 2023, 12 (03) : 503 - 513
  • [35] Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview
    Sanjiv J. Shah
    Journal of Cardiovascular Translational Research, 2017, 10 : 233 - 244
  • [36] Growth hormone resistance in chronic heart failure
    Anker, SD
    Volterrani, M
    Pflaum, CD
    Poole-Wilson, PA
    Strasburger, CJ
    Coats, AJS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 204A - 204A
  • [37] Growth hormone:: a new therapy for heart failure?
    Saccà, L
    BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1998, 12 (02): : 217 - 231
  • [38] Growth hormone and testosterone in heart failure therapy
    Agarwal, Megha
    Naghi, Jesse
    Philip, Kiran
    Phan, Anita
    Willix, Robert D., Jr.
    Schwarz, Ernst R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) : 1835 - 1844
  • [39] Growth hormone, vascular reactivity, and heart failure
    Napoli, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (Suppl 1) : 141 - 144
  • [40] The potential for growth hormone in the management of heart failure
    Monson, JP
    Besser, GM
    HEART, 1997, 77 (01) : 1 - 2